Volume : VIII, Issue : X, October - 2018

PEMBROLIZUMAB IN LUNG CANCER : LITERATURE REVIEW

R. Chacha, S. Afqir

Abstract :

Lung cancer is the first cause of death cancer in the worldwide.There is an important development of agents which aimed the PD–1/PD–L1 axis and that dhas a great influence on the strategy of the treatment of lung cancer in first and second line. Pemolizumab is approved by the U.S. FDA for the treatment of advanced NSCLC progressed after other therapies and with expression of PD–L1. This review highlights the results of recent clinical trials on pemolizumab for the treatment of non–small cell lung cancer.

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

R. Chacha, S. Afqir, PEMBROLIZUMAB IN LUNG CANCER : LITERATURE REVIEW, INDIAN JOURNAL OF APPLIED RESEARCH : Volume-8 | Issue-10 | October-2018

Number of Downloads : 194

References :